Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $88

Benzinga · 10/28/2025 16:00
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $76 to $88.